State of the art in fluid and volume therapy
Adequate intraoperative infusion therapy is essential for the perioperative outcome of a patient. Both hypo- and hypervolemia can lead to an increased rate of perioperative complications and to a worse outcome. Perioperative infusion therapy should therefore be needs-based. The primary objective is the maintenance of preoperative normovolemia using a rational infusion strategy. Perioperative fluid losses should be differentiated from volume losses due to surgical bleeding or protein losses into the interstitial space. Fluid loss via urine excretion or insensible perspiration (0.5–1.0 ml/kg/h) should be replaced with balanced, isooncotic, crystalloid infusion solutions in a ratio of 1:1. Volume therapy stage 1: intraoperative volume losses up to a blood loss corresponding to 20% of the patient’s total blood volume are compensated for by balanced crystalloids in a ratio of 4–5:1. Stage 2: blood losses exceeding this level are to be treated with isooncotic colloids (preferably balanced) in a 1:1 ratio. In this regard taking into consideration the contraindications, e. g., sepsis, burns, critical illness (usually patients in the intensive care unit), impaired renal function or renal replacement therapy, intracranial hemorrhage, or severe coagulopathy, artificial colloids such as hydroxyethyl starch (HES) can be used perioperatively for volume replacement. Stage 3: if an allogeneic blood transfusion is indicated, blood and blood products are applied in a differentiated manner.
KeywordsInfusions Colloid Hydroxyethyl starch Crystalloid Perioperative volume balance
Stand der Wissenschaft in der Flüssigkeits- und Volumentherapie
Eine adäquate intraoperative Infusionstherapie ist wesentlich für das perioperative Outcome eines Patienten. Sowohl Hypo- als auch Hypervolämie können zu einer erhöhten Rate perioperativer Komplikationen führen und somit zu einem schlechteren Behandlungsergebnis. Daher sollte die perioperative Flüssigkeitstherapie bedarfsgerecht und zielorientiert durchgeführt werden. Das Hauptziel ist die präoperative Normovolämie durch eine rationale Infusionstherapie aufrechtzuerhalten. Perioperative Flüssigkeitsverluste sollten dabei von Volumenverlusten durch chirurgische Blutungen oder Proteinverlusten ins Interstitium differenziert werden. Flüssigkeitsverluste via Urinexkretion oder Perspiratio insensibilis (0,5–1,0 ml/kg/h) sollten 1:1 mit balancierten, isoonkotischen, kristalloiden Infusionslösungen ausgeglichen werden. Volumentherapie, Stufe 1: Intraoperative Volumenverluste bis zu einem Blutverlust von 20 % des Gesamtblutvolumens werden mit balancierten Kristalloiden im Verhältnis 4–5:1 ausgeglichen. Stufe 2: Darüber hinausgehende Blutverluste sind im Verhältnis 1:1 mit isoonkotischen Kolloiden (bevorzugt balanciert) zu behandeln. In dieser Hinsicht und unter Beachtung der Kontraindikationen wie Sepsis, Verbrennungen, kritische Erkrankung (i. d. R. Patienten auf Intensivstation), eingeschränkte Nierenfunktion oder Nierenersatztherapie, intrakranielle Blutung oder schwere Gerinnungsstörungen können perioperativ auch künstliche Kolloide, wie z. B. HES, zum Volumenersatz verwendet werden. Stufe 3: Wenn die Indikation zur Gabe von Fremdblut besteht, erfolgt ein differenzierter Einsatz von Blut und Blutprodukten.
SchlüsselwörterInfusionen Kolloid Hydroxyethylstärke Kristalloid Perioperative Volumenbilanz
Water is a friendly element for anyone who is familiar with it and knows how to handle it.1
Johann Wolfgang von Goethe
Adequate infusion therapy represents a challenge for modern surgical, emergency, and intensive care medicine. Volume replacement solutions have been used for this purpose for decades. As their name indicates, these solutions serve as a volumereplacement, which is their original and also essential indication. As with all medications, volume replacement products have dose-dependent side effects too and should therefore only be applied in the presence of the corresponding indication. In recent years, several multicenter studies have stimulated an intense and sometimes emotional debate on the benefits and risks of hitherto existing pathophysiology-based treatment concepts.
But what is the objective of an adequate volume therapy?
The primary goal of perioperative fluid therapy is the extracellular space, which is divided into two functional compartments by the intact vascular barrier . The intention behind adequate volume therapy is maintaining normovolemia, extracellular homeostasis between the intra- and extravascular spaces (Fig. 1). In the perioperative period it seems reasonable to distinguish between fluid losses (extravascular space) without colloid-osmotically active molecules (such as urine and perspiratio) and volume losses (intravascular space), i. e., fluid with oncotically active macromolecules (blood or plasma losses from the intravascular space). These different entities are treated by the differentiated application of infusion solutions, crystalloids, and colloids . The way this can be successfully achieved is described below by a fundamental presentation of therapeutic options and their significance in terms of the risk–benefit ratio and by consideration of a practical case that could be encountered in daily practice. The concept of loss-adapted fluid and volume therapy is based on the patient’s preoperative normovolemia. This is normally present in patients without internal medicine complaints, despite fasting . As mentioned above, under normal conditions, the blood volume of a healthy individual remains physiologically very constant over the course of the entire day; it varies by only a few deciliter. Drinking is by no means the only regulatory factor: the permanent filtering and reabsorption of fluid out of and from the interstitial space plays a major role. A detailed description of the perioperative changes in hemodynamics induced by volume deficit or expansion would exceed the scope of this article; thus, this is intentionally not presented. However, in an illustrative case example of a situation that can arise any day in the operating room the effect of hypovolemia on hemodynamics and organ perfusion is exemplarily portrayed.
The foundation: efficiency, effectiveness, and evidence
Careful evaluation of efficiency, effectiveness, and evidence is essential for successful application of a particular medical treatment. To enable the reader to make his/her own best possible evaluation of the current data on fluid therapy, including understanding a viable infusion strategy, the genuine meanings of the terms efficiency, effectiveness, and evidence are explained in the following: Efficiency is the effort, in relation to completeness and accuracy, that is required to attain a particular objective. In contrast, effectiveness describes the degree to which the objective is attained (efficacy and quality). To enable these two terms to be understood more easily, the following practical example may be considered: After sport and sweating correspondingly, a fluid deficit of 500 ml can be efficiently and effectively treated by drinking water. Leaving aside cost considerations, drinking 500 ml of prosecco or even whiskey would be just as efficient in this instance. In terms of treatment of the fluid deficit alone, all three “therapeutic” regimens can be considered equally efficient and effective; however, drinking prosecco or whisky is associated with additional “side effects.” The effectiveness of a treatment must, thus, always be seen broader than as an achievement of the therapeutic goal. Efficiency is important, but if the wrong things are efficiently accomplished, then this constitutes a waste of resources and a risk for the patient. Strategy (effectiveness) thus comes before efficiency in fluid therapy, too. Completing the circle, the question of the safety of a therapy and the corresponding evidence demonstrating that the benefits outweigh the risks always arises, too. Evidence – and this is very important – means “proof.” Evidence in medicine refers to the empirical verification of the benefit of a diagnostic or therapeutic action. This forms the basis of evidence-based medicine.
Types of evidence according to Cochrane
Type of evidence
At least one systematic review based on methodologically high-quality randomized controlled trials (RCTs)
At least one sufficiently large, methodologically high-quality RCT
At least one high-quality non randomized study
At least one high-quality study of another type of quasi-experimental studies
More than one methodologically high-quality non experimental study
Opinions and recommendations of respected authorities (from clinical experience); expert commissions; descriptive studies
Therefore, it can not be excluded that guidelines are, to some extent, influenced by the evaluations or even wishes of pharmaceutical companies.
“Absence of evidence is not evidence of absence!” This means: If there is no evidence for a therapy, this still is not a license to proceed at will. Consider the following currently relevant example of liver transplant and alcohol consumption, which also has to do with fluids: In light of the fact that there is no evidence demonstrating the benefit of abstinence from alcohol prior to transplantation, its importance is currently the subject of debate. “The required 6‑month period of abstinence from alcohol excludes patients from a potentially life-saving treatment. In light of the far-reaching consequences of this regulation, special demands are to be placed on the reliability of the underlying evidence: The data should demonstrate clearly that the survival times of relapsed patients are significantly reduced by the renewed consumption of alcohol” . The concept of evidence-based medicine is misunderstood here: It is well known that alcohol (even in small quantities) can have hepatotoxic effects. Clinical experience has shown that in a nonnegligible number of patients a rapid improvement in organ function due to alcohol abstinence because of their potential listing for a potential liver transplant renders the transplant no longer necessary. Furthermore, it cannot be doubted that alcohol will continue to have an hepatotoxic effect after the transplantation – a transplanted liver is not “alcohol resistant.” Purely because no “evidence” is available, i. e., there are no sufficiently large controlled studies clearly proving these correlations in this special population, the universally valid pathophysiology or “common knowledge” must not be ignored. This is also true for infusion therapy, e. g., gelatin: There is a lack of large controlled trials with the corresponding long-term follow-up to prove that gelatin is not safe (see also below “Evidence in volume therapy: Gelatin”). However, the lack of these data of course does not prove the safety of this infusion solution.
“Presence of evidence is evidently present!” For example, if it has been shown in controlled studies, i. e., blinded prospective randomized trials, that the adverse effects of a treatment outweigh the benefits in a particular patient collective, this result cannot be “topped” or refuted by studies of a lower-level evidence type, such as register or observational studies. Available evidence cannot be negated in this manner, even if certain representatives of profit-oriented pharmaceutical companies would understandably wish to see it otherwise.
Since in clinical routine there are sometimes situations in which clinicians occasionally do not know what to do, volume therapy is sometimes not performed according to the findings of the large studies and metaanalyses, but rather empirically, based on “gut feeling.” However, which sustained findings concerning infusion therapy can be provided by physiology and evidence-based medicine?
Physiology and effectiveness in infusion therapy
Fluid therapy comprises administration of crystalloids and colloids. Crystalloids are solutions of water and electrolytes; colloids also contain substances with water-binding properties, e. g., albumin, hydroxyethyl starch (HES), or gelatin. The type and composition of the solution to be infused should be adapted to the fluid compartment that is the target of therapy. This is the reason for the development of, e. g., isotonic infusion solutions. As already mentioned, it must be discriminated between fluid losses with and without loss of oncotically active macromolecules. From this results the differentiation of volume losses out of the intravascular and interstitial spaces (loss of oncotically active macromolecules, e. g., albumin) from fluid losses such as urine, insensible perspiration (quantitative 0.5 ml/kg/h, with maximal eventration 1 ml/kg/h), or preoperative dehydration (no loss of oncotically active macromolecules, but pure fluid deficit). With each episode of blood loss, patients lose a sometimes considerable amount of protein – depending on the amount of blood loss. Therefore, if blood loss is compensated for to a large extent using pure crystalline solutions, the colloid osmotic pressure in the blood vessel system will drop significantly. Moreover, during major tumor surgeries, considerable quantities of macromolecules – protein and HES – are lost into the interstitial space, the so-called protein  or HES shift [14, 15, 16]. These are losses of protein or HES that can not be explained by surgical bleeding or urine. For example, in ovarian cancer patients, in addition to the protein loss resulting from surgical bleeding (1700 ml, 67 g protein loss), a mean intraoperative protein shift of 49 g occurred . In patients with radical hysterectomy, it was shown that 30% of the applied HES molecules left the vascular bed (mean loss via surgical bleeding: 18 g, mean excretion of HES in urine: 18 g, mean HES shift: 30 g) . Both HES or protein loss via surgical bleeding and the shift of protein or HES into the interstitial space reduces the intravascular colloid osmotic pressure, thus, exacerbating edema formation due to extravasation of fluid.
In order to develop a viable strategy to replace all of these fluid and colloid osmotic pressure losses in a demand-oriented manner, it is important to know how effective the various available infusion solutions are.
The vascular barrier
Evidence in fluid therapy
Perioperatively and in the intensive care units, the use of balanced isotonic crystalline solutions is increasing. This is because physiologic saline solution causes hyperchloremic acidosis in a dose-dependent manner . In comparison to balanced solutions, this reduces splanchnic bed and renal perfusion, reduces urine excretion, and increases the incidence of nausea and vomiting . There are also indications that balanced solutions are associated with advantages in terms of patient survival . But in contrast, a recently published study found no survival benefit of balanced solution compared to saline solution ; however, the applied amount of infusion was so small in this study (<2 l applied slowly during the course of several days) that neither the chloride concentration nor the pH in the saline group could increase above or drop below the respective normal values. At ISICEM 2016, Kellum presented results from a very large cohort of patients demonstrating that larger amounts of saline solution were associated with increased mortality compared to balanced solutions. These results were published as the current article was in press . Contrary to widespread belief, the potassium content of balanced solutions does not cause hyperkalemia in renal insufficiency patients [35, 36]. In fact, it has been shown for kidney transplantation that even in the anuric phase a potassium-containing (up to 5 mmol/l) balanced solution is superior to 0.9% NaCl . This is because the hyperchloremic acidosis caused by saline solution promotes potassium drift from the intracellular space into the intravascular space, which favors hyperkalemia. Even infused in large amounts, a balanced infusion solution with a potassium content of 4–5 mmol/l cannot cause hyperkalemia, since it is not hyperkalemic. Only if the patient has a pronounced pure water diuresis could balanced solutions theoretically lead to hyperkalemia (concentration effect due to water loss via the kidneys). In summary, it therefore appears rational to use balanced infusion solutions in intensive care medicine and in the OR, and to apply isotonic saline solutions only in special situations, e. g., cholera (substained losses of chloride and sodium).
Albumin is a 585-amino acid protein with a molecular weight of 69 kDa. Albumin-containing infusion solutions are extracted from human blood (and thus require a batch manufacturing record), are considered as virus safe, and can be used to treat hypoalbuminemia. Although albumin level is a frequently measured clinical parameter, no generally valid minimum limit can at present be defined below which replacement should take place. It has been repeatedly demonstrated that pronounced hypoalbuminemia in critically ill patients is associated with poor outcome . Whether or not hypoalbuminemia was indeed the cause of the poor outcome or rather symptomatic of the severity of each particular disease (e. g., nutritional status, degree of inflammation) is still controversially discussed. However, in cases of severe hypoalbuminemia (<2.5 g/dl), there are many indications that albumin administration seems to be beneficial in terms of mortality, organ function, the amount of fluid to be applied (fluid balance), and tolerance of enteral nutrition [37, 38, 39, 40, 41]. The endothelial glycocalyx requires a low but nevertheless basal albumin concentration for maintenance of its barrier function. For a long time, albumin was considered the virtually ideal volume substitute, due to its colloid osmotic properties and long intravascular retention time. The volume effect of 20% albumin solution is 185%, which means that this infusion solution can recruit fluid from the interstitial space for the intravascular space. The volume effect is higher than the entire volume of the infused solution. Albumin 5% has a volume effect of 85%, meaning that almost all of the infused fluid remains in the vascular system. Albumin was thus used for decades as the reference substance during development of artificial colloidal plasma replacement products. Since the development of cheaper artificial colloids, the application of albumin as a volume replacement product has decreased considerably. An older Cochrane analysis demonstrating increased mortality among critically ill patients receiving albumin contributed significantly to this trend . Volume replacement with albumin was subsequently investigated in several large-scale prospective trials. The Australian SAFE trial investigated the safety of infusion therapy with human albumin in intensive care patients [43, 44] and was unable to show any severe adverse effects compared to 0.9% saline infusion; nor, however, was the outcome of the albumin-treated patients better [43, 44]. The ALBIOS trial evaluated a patient collective with severe sepsis or septic shock. The experimental group received albumin replacement (not for volume therapy, but rather to increase the serum albumin concentration to ≥3 g/dl) and the control group received only crystalloid solution . There was no difference in terms of mortality between the two groups . In the similarly conceived EARSS trial, a reduction in absolute and relative mortality of 2.2% and 8.4%, respectively, was observed in the human albumin group compared to the crystalloid group after 28 days (p > 0.05) . Wiedermann’s meta-analysis  of pooled data from the SAFE, EARSS, and ALBIOS trials reported that albumin application in patients with severe sepsis or septic shock was associated with significantly reduced mortality (p = 0.046). An almost simultaneously published meta-analysis did not arrive at this result (p = 0.08); however, this study also included patients from two other very small studies, which were not designed and standardized for addressing the endpoint “outcome” (unfortunately, this is a frequent shortcoming of meta-analyses). Additionally, this study did not use the correct patient numbers from the original ALBIOS study publication . In contrast to hyperoncotic HES solution, no negative impact of albumin on renal function could be shown .
Whether the positive effects of infusions are realized or are outweighed by their adverse effects, however, always depends on the applied dose and a correctly established indication. It was shown that mortality in children with a severe infection significantly increased following application of a large fluid bolus (albumin or isotonic saline solution; 20–40 ml/kg). However, in comparison over 90% of the children had no clinical signs of hypovolemia . Application of high doses of infusion solutions in the absence of volume requirements must be viewed critically, irrespective of the type of solution. However, use of human albumin as volume replacement for stabilization of hemodynamics is nowadays widely accepted.
In summary, the base of high-quality data (level of evidence Ia) confirms the effectiveness, efficiency, and safety of human albumin. These data are not only available from sufficiently large RCTs, but also from significant meta-analyses of these RCTs (Table 1). Compared to synthetic colloids, human albumin is a very expensive treatment option . For this reason, albumin should not be used where other therapeutic alternatives (e. g., crystalline solutions or synthetic colloids) are possible. Two post hoc analyses demonstrated reduced mortality in severe sepsis (SAFE) and septic shock (ALBIOS) achieved by albumin application. It would be wrong to conclude that this demonstrates that albumin is an effective treatment for sepsis. Administration of antibiotics as early as possible and a causal treatment (e. g., curing of infection) is undoubtedly far more effective. However, many available data indicate that hypoalbuminemia (<2.5 g/dl) in sepsis patients should be treated early by appropriate administration of albumin [43, 47, 52, 53]. Therapeutic target should be an albumin concentration of over 2.5 g/dl, which is most effectively achieved with a hyperoncotic albumin solution (albumin 20%).
Hydroxyethyl starch (HES)
HES solutions are synthesized from plant-derived starch (waxy corn or potato starch). A proportion of the cyclic glucose rings in the starch is substituted with hydroxyethyl groups. For example, the indication 130,000/0.4 means that the starch, with a molecular weight of 130,000 Da, carries hydroxyethyl groups on 40% of the glucose rings. The volume effect of HES 130,000 is almost 100% and can thus be described as ideal in terms of volume replacement. Although various smaller studies in different patient cohorts found no negative effects due to the application of HES as part of a combined HES and electrolyte solution therapy, studies in intensive care medicine have revealed a different picture. The VISEP trial in patients with severe sepsis found a negative effect on renal function, which was frequently observed only at later time points (observation time was 90 days) . In this study, an older HES preparation was used in a hyperoncotic form (10%) and administered to a high cumulative dose. The blinded randomized prospective 6S trial  compared treatment with 6% HES 130,000/0.42 with Ringer’s acetate application in sepsis patients. This study also revealed an increased rate of renal replacement therapy and, furthermore, increased mortality following HES therapy. Another blinded randomized prospective study, the CHEST trial, investigated a large mixed cohort of patients requiring postoperative intensive care, but of whom the majority were not septic patients . This study showed an increased rate of renal replacement therapy following HES treatment (p = 0.04) and no difference in mortality after 90 days, although circulatory stabilization was achieved more quickly using HES volume replacement. Also the CRYSTMAS trial  investigated a sepsis patient cohort and demonstrated that HES 130,000/0.4-based volume replacement therapy resulted in more rapid hemodynamic stabilization compared to 0.9% saline solution. This trial found no significant difference between the groups in terms of renal function and mortality, which may be due to the comparatively small number of patients (n = 174).
Meta-analyses containing these intensive care medicine RCTs (level of evidence Ia) demonstrate that in critically ill patients, particularly in those suffering from sepsis or septic shock, application of HES is associated with an increased incidence of renal failure and a higher rate of renal replacement therapies [58, 59, 60]. Subsequently, on the basis of these results, in October 2013, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency issued the recommendation that HES should no longer be used in critically ill patients as well as those suffering from sepsis or burns. Additionally, it was also recommended not to continue HES treatment for more than 24 h and to monitor renal function for 90 days [61, 62].
short time interval between shock event and randomization,
limited use of initial fluid therapy,
consistent use of a fixed infusion algorithm until hemodynamic stabilization,
reproducible criteria for hypovolemia,
maximum doses of HES,
exclusion of patients with preexisting impaired renal function or renal replacement therapy.
The studies mentioned above only partially fulfill these criteria . So far, controlled trials fulfilling all criteria mentioned above, with high case numbers and long observation period of at least 90 days, are unfortunately not available. Whether HES 130,000/0.4 has a more favorable safety profile in sepsis patients and is thus associated with a lower rate of renal function-related adverse events in long-term follow-up compared to older starch preparations is currently unclear . Therefore, no HES preparations at all should be used in this special patient collective (see also section “Practical conclusion – the synopsis”). By way of precaution, the German Society of Anesthesiology and Intensive Care Medicine (DGAI) recommends that the application of modern low molecular HES solutions in intensive care patients should be evaluated critically on an individual basis and that their use should be restricted to patients with acute life-threatening blood and volume losses not manageable by other means. This means, for example, that a patient having undergone aortic stent grafting, who is postoperatively only in the intensive care unit for monitoring purposes and suddenly suffers massive hypovolemic shock due to aortic rupture, can of course receive larger amounts of HES as an already initially lifesaving treatment, even though the situation takes place in the intensive care unit.
Do these considerations also apply to the use of HES preparations as a volume replacement solution in the OR?
After the regulatory authorities initially suspended the entire approval for HES preparations, it was also no longer permitted to use these during surgery for a while. In two industry-supported meta-analyses, the safety of cornstarch 130,000/0.4 was investigated in a large number of surgical patients. The authors found no significant difference to the control group and attested to the safety of this cornstarch. However, the majority of the included studies had insufficiently long observation periods and no real control group. A further study without industry funding came to the same conclusion with the same shortcomings of the included studies . To prove the safety of HES in the OR – analogous to intensive care medicine – correspondingly conceived, randomized, controlled, and blinded trials are also required. Results from studies of this type are not yet available .
Where evidence is insufficient, pathophysiologic considerations will help: The potential nephrotoxic properties of HES 130,000/0.4 have almost exclusively been demonstrated in seriously ill intensive care patients to date. It seems highly likely (even though this may be speculative) that patients with normal renal function are considerably less sensitive to the potential nephrotoxic effects of HES 130,000/0.4 than intensive care patients who are already seriously ill. If these patients are not treated with colloids in the event of loss of larger amounts of blood, either very large amounts of crystalloids are required – with all the adverse effects of the resulting positive fluid balance – or the unavoidably arising hypovolemia with hypotension and subsequent vasopressor application will very likely endanger renal function. However, this dilemma can be solved by considering the effectiveness: If a nephrotoxic effect of HES 130,000/0.4 is present at all in otherwise healthy patients in the OR, then the data from intensive care medicine indicate that HES-associated perioperative renal failure is likely to be a rare event, since even in this patient collective very high case numbers are required in order to detect this effect. In contrast, prerenal acute kidney failure is much more likely to be caused by severe hypovolemia. This “effect-based” risk analysis clearly favours the use of HES 130,000/0.4 for correctly indicated treatment of larger blood losses in the OR. If one wishes to eliminate every risk, even a theoretical risk, then the expensive albumin preparations discussed above must also be used in the OR.
A further potential adverse effect of HES 130,000 is its – albeit minor – negative impact on blood coagulation, which goes beyond the effect of simple dilution of coagulation factors . This and the potential impairment of renal function provide the reason for dose limitation (30 ml/kg). A recently published meta-analysis showed that HES application can result in a larger intraoperative blood loss compared to crystalloid therapy alone . However, it must be noted that larger blood losses are often not appropriately treated by the sole application of crystalloid. The drop in blood pressure caused by hypovolemia can itself decrease blood losses. Slightly reduced blood losses should not be an argument for neglecting the objective of demand-oriented maintenance of normovolemia, since the predominant application of vasopressors for the compensation of a volume deficit can seriously impair perfusion of organs such as the kidneys.
The concept propagated in the past, namely that patients be prophylactically “volume loaded” prior to surgery, e. g., by HES application, should also be viewed critically, due to the possible impairment of the vascular barrier function . This also applies to Caesarean section patients, since the safety of artificial colloids for mother and child has not yet been sufficiently proven (by RCTs with high case numbers and long-term follow-up). Pregnant women generally have a high normal blood volume prior to parturition per se, which does not have to be and should not be expanded by artificial colloids. In summary, considering the contraindications, the use of HES preparations for compensation of larger blood losses in the OR can be endorsed. As long as sufficiently large controlled studies with long-term follow-up are lacking for the perioperative phase, it is impossible to exclude completely a residual risk (e. g., for renal function).
Alongside HES, gelatin is another artificial colloid employed in the clinical use. Gelatin is a very heterogeneous polypeptide mixture made from the collagenous connective tissue of cattle specially bred for this purpose. Since a part of the applied amount is eliminated via the kidneys already during its infusion, a volume effect of 50–100% can be expected, depending on the preparation [20, 51]. However, this volume effect is only maintained for a maximum of 2 h. The effects on blood coagulation are even less pronounced than with HES preparations. However, intolerance reactions of all degrees of severity have been described for gelatin preparations. It is certain that gelatin preparations elicit the highest rate of anaphylactic reactions of all artificial and natural colloids . Due to the bovine raw material, contamination of gelatin with the agent responsible for causing the new variant of Creutzfeldt-Jakob disease cannot be completely ruled out. Although a chemically very aggressive manufacturing procedure can massively reduce the prions, it cannot completely eliminate them. In the era preceding the first cases of bovine spongiform encephalopathy (BSE) in Germany, the theoretic risk of BSE transmission via gelatin was calculated to be <1:1000000 . In the USA, gelatin solutions are no longer approved; in Germany an obligation for batch documentation is discussed. Animal experiments have shown that gelatin can cause histopathologic changes in the kidneys, such as vacuolization of tubule cells (“osmotic nephrosis-like lesions”) . In critically ill patients, a cumulative gelatin dose >33 ml/kg body weight, is associated – as for HES – with a higher incidence of renal failure .
In contrast to the large amount of data available for HES preparations or albumin, there are currently no large randomized studies demonstrating the safety and benefit of treatment with gelatin preparations [67, 68]. According to a 2012 Cochrane analysis, data from RCTs are available for HES from 9147 patients and for albumin from 9920; gelatin, however, has only been subject to controlled investigation in this context in 506 patients . “Absence of evidence” of course does not mean that the preparations can be applied in intensive care medicine or in the OR without hesitation. The fact that there is currently no sufficient evidence for the safety of gelatin solutions – neither in intensive care units nor in OR – does not support their use, but must be assessed as a considerable disadvantage of gelatin compared to albumin and HES [61, 67].
The three-stage concept of volume therapy
Stage one: basal crystalloid therapy
Fluid losses (urine and insensible perspiration) are replaced in a 1:1 ratio with a balanced crystalloid infusion solution. Additionally, intravascular blood loss must be replaced in a 4–5:1 ratio. This is where the limitation of basal crystalloid therapy is encountered, since this means at the same time the infusion of 80% “interstitial edema”. As already mentioned, establishment of a highly positive fluid balance should not be considered harmless [1, 3, 4, 5, 8, 24, 71]. A limit must therefore be defined, above which basal crystalloid therapy is replaced by a treatment of higher effectiveness, in order to avoid the complications and adverse events associated with fluid overload. As a rule of thumb, blood loss corresponding to 20% of the initial blood volume can be stated as the limit. Since most patients in the OR only experience blood losses within this order of magnitude, according to this concept, the majority of patients can be treated without colloid.
Stage two: blood losses exceeding 20% of the initial blood volume
Blood loss should be replaced by an effective colloid therapy to prevent the fluid balance becoming too positive. Fluid losses (urine and insensible perspiration) are still replaced in a 1:1 ratio with crystalloids. The largest volume effect has been described for 20% human albumin (Table 2). However, this is also by far the most expensive colloid. Considering the contraindications, artificial isooncotic colloids such as HES may also be used in stage two (1:1 ratio in relation to the blood losses exceeding that of stage 1).
Stage three: for very large blood losses
The use of infusion solutions (stages 1 and 2) is limited by the increasing development of anemia and impairment of blood coagulation resulting from the dilution. In addition to the dilution of coagulation factors by the maintenance of normovolemia with decreasing blood volume, gelatin and HES 130,000 also have direct negative effects on blood coagulation. Anemia and the loss of coagulation factors necessitate a differentiated and demand-oriented transfusion of blood products (erythrocyte concentrates, EC; fresh frozen plasma, FFP; thrombocyte concentrates; coagulation factors).
Application of this staged concept ensures a loss-adapted and therefore needs-based volume therapy. However, the three stages should not be followed too dogmatically! For example, should one of the large veins suddenly tear – leading to loss of a large amount of blood within just a few minutes – stage 2 should and must be implemented immediately, since the volume loss must be treated with infusion solutions of high effectiveness without delay. In this scenario, sufficient amounts of colloids should be applied immediately (e. g., 1–2 l of HES) to prevent intraoperative hypovolemia. Blood products may also be administered early.
The example in the following section highlights the importance of correctly defining the fluid and volume requirements; it illuminates the perils of intraoperative infusion therapy on one hand, but also provides important simple hints and tricks on the other.
A practical example – volume therapy explained using simple math
general anesthesia and administration of epidural anesthesia
Hb 12.3 g/dl, Hct 39.3%
norepinephrine 0.3 mg/h
- 1 h after the beginning of surgery:
Hb 9.2 g/dl, Hct 29.4%
norepinephrine 0.5 mg/h
cumulative 1500 ml of crystalloid infused
- 2 h after the beginning of surgery:
estimated blood loss in towels and aspirators 1500 ml
urine excretion 500 ml
Hb 8.2 g/dl, Hct 26.2%
norepinephrine 1.5 mg/h
cumulatively 5000 ml of crystalloid infused
- 3 h after the beginning of surgery:
surgeon complains of impaired blood coagulation and sustained surgical bleeding
administration of three fresh frozen plasma (FFP) (750 ml)
Hb 7.0 g/dl, Hct 22.4%
norepinephrine 1.8 mg/h
infusion of another 1000 ml of crystalloid solution
administration of four red cell concentrates (cumulative total of 1200 ml)
- 4 h after the beginning of surgery:
Hb 7.7 g/dl, Hct 24.6%
norepinephrine 1.2 mg/h
administration of another three FFP (cumulative total of 1500 ml)
thereafter Hb 7.5 g/dl and Hct 24.0%
estimated total blood loss 3000 ml
total urine excretion 700 ml
- End of surgery 5 h after the beginning of surgery:
Hb 7.9 g/dl, Hct 25.3%
norepinephrine 0.6 mg/h
Overview of fluid balance at the end of surgery
Fresh frozen plasma
Why did circulatory / cardiovascular instability and renal failure develop in this patient?
The mathematical solution of this case
Practical tip: BSA can be calculated using tools available online. For a simplified calculation of blood volume, BV =60 ml/kg can be used, although this is less precise than calculations using BSA.
Practical tip: if only Hb values are available, Hct can be calculated using: Hb (g/dl) ×3.2 =Hct. This requires a normal mean corpuscular hemoglobin concentration (MCHC), which, however, is the case in the vast majority of patients.
Provided the patient remains indeed normovolemic, using the blood volume, it is possible to calculate at every particular timepoint the corresponding erythrocyte volume and thus the change in erythrocyte volume (∆EV) as well as blood loss using the mean Hct value.
Evaluation of volume therapy at the point in time 2 h after incision
The estimated and the calculated blood loss values were almost identical at this point in time. With a cumulative administration of 5000 ml crystalloid solution, the fluid balance was +2727 ml (calculation: 5000 ml of crystalloid − 134 ml of perspiration − 500 ml of urine − 1639 ml of blood loss). However, despite this, the administered volume therapy was not sufficient.
Overview of the volume balance for the intravascular space 2 h after incision
Urine and perspiration
Crystalloid for fluid replacement
Amount of crystalloid accreditable to compensation of blood loss
(crystalloid at measurement −637 ml) ×20% = (5000 ml − 637 ml) × 20%
Therefore: At this point in time the patient had a pronounced intravascular hypovolemia (756 ml), which explains the cardiovascular instability and the requirement for 1.5 mg/h of norepinephrine. According to the three-stage concept (see section “The three-stage concept of volume therapy”), the critical value of blood loss corresponding to 20% of the preoperative blood volume should have been calculated first. In a patient with an approximate blood volume of 4000 ml, this corresponds to a blood loss of 800 ml. In stage 1, 4–5-times this amount of blood loss, plus the losses due to urine excretion and perspiration, should have been replaced with crystalloid. This corresponds to approximately 4600 ml (5 × 800 ml + 637 ml). Thereafter, stage 2 should have been observed and further blood losses should have been replaced with colloids. In this example, 800 ml of HES would have been indicated.
Situation at the end of surgery
The calculation of blood loss proceeds analogously to the calculation above for the time point 2 h after the start of surgery.
Overall evaluation: Target missed! Pronounced hypovolemia despite a highly positive fluid balance
Overview of the volume balance for the intravascular space at the end of surgery
Urine and perspiration
Crystalloid for fluid replacement
Amount of crystalloid accreditable to compensation of blood loss
(crystalloid at measurement time −1035 ml) ×20% = (6000 ml − 1035 ml) × 20%
Fresh frozen plasma
The patient had a severe hypovolemia postoperatively (over 1200 ml volume lacking)! Furthermore, in addition to bleeding during these surgical procedures, large intraoperative protein losses also occur, which have not been included in the calculations presented here.
In summary, in this situation with a blood loss of almost 5 l, the administered volume therapy was not demand-oriented. Less crystalloid but considerably more “volume” (colloid) would have been loss-adapted and the infusion of 2000 ml of HES appropriate. The presented example also demonstrates something fundamental: In patients without internal medicine complaints, if during major surgery a gradual pronounced increase in catecholamine requirement is observed, this is a very strong indication that blood loss is being treated inadequately! The following is, however, speculative: The pronounced hypovolemia with correspondingly high catecholamine requirement had a more severe impact on renal function than “defense” of normovolemia using HES would have had in this renally healthy, noncritically ill patient.
Important comments for bedside blood loss calculation
As shown in Fig. 3, in the incidence of bleeding and normovolemic dilution with infusion solutions, Hct decreases logarithmically . Owing to the simpler mathematics, the calculation of blood loss presented above is not logarithmic, but rather linear. If, for example, only two Hct measurements are made during a bleeding (example 1), then Hctm will be considerably too high and the calculated blood loss therefore too low. It is thus always preferable to input several Hct values into the calculation. In the discussed example, seven Hct measurements were performed (Fig. 3, example 2). Although this is a sufficiently high number, the Hctm will still be somewhat too high and the calculated blood loss will therefore be an underestimation of the actual blood loss. This means that potential hypovolemia and the linearity of the calculation can result in the calculated blood loss being lower than the actual blood loss. However, as the example demonstrates, even a blood loss calculated still too low provides a far better overview than a pure estimation of blood loss, which is unfortunately a very unreliable parameter. Factors contributing to this unreliability include the fact that the losses in towels are very difficult to estimate, blood can flow into unseen regions which the surgeon does not aspirate, and even the blood content of aspirators is difficult to estimate due to rinsing solutions, particularly in case of large blood losses. Unfortunately, considerable underestimation of intraoperative blood losses is thus a frequent event . Therefore, the bedside blood loss calculation presented herein is extremely useful and can even be implemented in anesthesia documentation programs.
Practical conclusion – the synopsis
should be needs-based, with the aim of normovolemia,
should be loss-adapted and distinguish between fluid and volume losses,
should balance out fluid losses (urine and insensible perspiration 0.5–1.0 ml/kg/h) with a balanced crystalloid infusion solution in a 1:1 ratio,
should first compensate volume losses (intraoperative blood loss) corresponding to up to 20% of the total blood volume with balanced crystalloids in a 4–5:1 ratio, and treat blood losses exceeding this level with isooncotic colloids in a 1:1 ratio.
critically ill patient (usually in the intensive care unit),
impaired renal function or renal replacement therapy,
intracranial or cerebral bleeding,
severe coagulation disorder
HES can also be used for volume replacement. In patients with a contraindication to HES, albumin solutions should be preferred to gelatin solutions, since there are data available supporting the safety of albumin infusions.
Stage 1: basal crystalloid therapy. Fluid losses (urine and insensible perspiration) are replaced by a balanced crystalloid infusion solution in a 1:1 ratio. Intravascular blood loss must be additionally compensated in a 4–5:1 ratio.
Stage 2: blood losses exceeding 20% of the initial blood volume. Application of colloids (preferably balanced) in a 1:1 ratio for replacement of blood losses exceeding those of stage 1. Fluid losses (urine and insensible perspiration) continue to be replaced in a 1:1 ratio by a balanced crystalloid infusion solution.
Stage 3: very large blood losses. Differentiated and needs-based transfusion of blood products, i. e., red cell concentrates and FFPs (adapted to the present coagulation), as well as coagulation factors and thrombocyte concentrates as required.
Bedside blood loss calculation based on normal blood volume and intraoperative Hb or Hct measurements provides the anesthetist with a very good orientation, which renders the objective–maintenance of normovolemia in the patient–easier to achieve. Disregarding coincidences, a fluid and volume therapy can only be needs based if the patients’ requirements are known.
Compliance with ethical guidelines
Conflict of interest
M. Rehm is currently directing two clinical studies, one of which is supported by CSL Behring and the other of which is supported by Fresenius Kabi. He has received no travel expenses or honoraria from pharmaceutical companies during the past 2 years. N. Hulde, T. Kammerer, A.S. Meidert, and K. Hofmann-Kiefer declare that they have no competing interests.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 10.Fachgesellschaften_AAWM (2014) Intravasle Volumentherapie beim Erwachsenen (Registernummer 001–020)Google Scholar
- 11.Langer T, Conrad S, Fishman L et al (2012) Interessenkonflikte bei Autoren medizinischer Leitlinien. Eine Analyse der Leitlinien deutscher Fachgesellschaften 2009–2011. Dtsch Arztebl 109:836–842Google Scholar
- 12.Marckmann G (2015) Alkoholabstinenz vor Lebertransplantation: Contra. Dtsch Arztebl 112:A 279Google Scholar
- 15.Jacob M, Chappell D, Hofmann-Kiefer K, Conzen P, Peter K, Rehm M (2007) Determinants of insensible fluid loss. Perspiration, protein shift and endothelial glycocalyx. Anaesthesist 56(747–58):60–64Google Scholar
- 19.Rehm MHM, Brechtelsbauer H, Akbulut C, Finsterer U (1998) Changes in plasma volume in immediate pre- and postoperative periods in patients major gynecologic surgery. Infusionsther Transfusionsmed 25:222–228Google Scholar
- 34.Senn A et al (2017) Chloride content of fluids used for large-volume resuscitation is associated with reduced survival. Crit Care Med 45:e146–e153Google Scholar
- 46.Charpentier JJ-PM (2011) Efficacy and tolerance of hyperoncotic albumin administration in septic shock patients: The EARSS study. Intensive Care Med 37:115Google Scholar
- 51.Rehm M, Paptistella M, Dieterich HJ (2012) Volumenersatzlösungen, 3 edn. Springer, Berlin, HeidelbergGoogle Scholar
- 60.Zarychanski R, Turgeon AF, Fergusson DA et al (2009) Renal outcomes and mortality following hydroxyethyl starch resuscitation of critically ill patients: systematic review and meta-analysis of randomized trials. Open Med 3:e196–209 (ATTENTION: The analysis and conclusions of this article are being revised by the authors. This is due to the journal Anesthesia and Analgesia’s retraction of a paper by Dr. Joachim Boldt, an author in seven of the studies analyzed in this review. As such, the editors of Open Medicine recommend interpreting this review with extreme caution until Zarychanski et al. publish a new analysis and interpretation in Open Medicine. For more information, see Anesthesia and Analgesia’s press release)PubMedPubMedCentralGoogle Scholar
- 62.European Medicines Agency. Assessement report for solutions for infusion containing hydroxyethyl starch. EMA/667553/2013Google Scholar
- 63.Meybohm P, Van Aken H, De Gasperi A et al (2013) Re-evaluating currently available data and suggestions for planning randomised controlled studies regarding the use of hydroxyethyl starch in critically ill patients – a multidisciplinary statement. Crit Care 17:R166CrossRefPubMedPubMedCentralGoogle Scholar
- 75.Jacob M, Bruegger D, Conzen P, Becker BF, Finsterer U, Rehm M (2005) Development and validation of a mathematical algorithm for quantifying preoperative blood volume by means of the decrease in hematocrit resulting from acute normovolemic hemodilution. Transfusion 45:562–571CrossRefPubMedGoogle Scholar